St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
NCT Number: NCT01344941
The primary objectives of this study is to
* Define the envelope-specific B-cell and T-cell responses in humans who have received a St. Jude HIV-1 vaccine. * Describe mechanisms of HIV-1 envelope processing and consequent B-cell and T-cell activities.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Memphis, Tennessee, 38105, United States
The goal of this protocol is to understand how human lymphocytes respond to HIV-1 antigens in the context of vaccination or infection. This protocol will support understanding of the immune response by providing a source of lymphocytes and serum from selected individuals to study in laboratory based investigations. Blood samples from individuals who have received an HIV-1 vaccine, individuals who are HIV-1-infected, and individuals who are HIV-1-uninfected are requested to: (1) test previously vaccinated volunteers for HIV-1 envelope-specific B-cell and T-cell immune activities, and (2) increase understanding of how the human immune system processes and responds to HIV-1 envelope proteins.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Group 1 (Vaccinees) only Inclusion Criteria:
Group 2 (HIV positive) only Inclusion Criteria:
Group 3 (HIV negative) only Inclusion Criteria:
Exclusion criteria
Group 2 (HIV positive) only Exclusion Criteria:
Time frame: 5 years
The outcome measures will be assessed in such a way that individuals will be sampled longitudinally (every 6months) until the immune response is no longer detectable by HIV ELISA or until the 5 year study period is complete, whichever comes first. A volume of 120 ml will be collected at each visit for immune response assays (both B-cell and T-cell) and 2 ml of blood will be collected for the HIV ELISA.
Time frame: 5 years
The outcome measures will be assessed by new developments in the field that may ultimately yield improved methods for the testing of antigen processing and B-cell and T-cell functions, in which case new assays will be adopted for use in this study. Lymphocyte samples will also support HLA testing. Samples will be used for continued B-cell and T-cell studies supportive of the 2 study objectives. The volume of blood drawn will be closely monitored and will remain below the defined criteria for minimal risk research.
St. Jude Children's Research Hospital
Other
Acronym: HIVBLD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06908252
Blood-Borne Infections, Communicable Diseases
Durham, North Carolina, United States
View Trial DetailsNCT01621347
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT01322932
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT01621412
Behavior, Blood-Borne Infections
Lausanne, Canton of Vaud, Switzerland
View Trial Details